Description: SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
Home Page: synactpharma.com
Medicon Village
Lund,
223 81
Sweden
Phone:
46 1 03 00 10 23
Officers
| Name | Title |
|---|---|
| Mr. Jeppe Ovli Ovlesen EE, MBA | CEO & Director |
| Mr. Bjorn Westberg | Chief Financial Officer |
| Dr. Thomas Boesen Ph.D. | Chief Operating Officer |
| Mr. James Knight M.B.A. | Chief Business Officer |
| Ms. Kristen Harting M.D. | Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.3567 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |